CN109195989A - 用于癌症治疗的pd-1/pd-l1抑制剂 - Google Patents

用于癌症治疗的pd-1/pd-l1抑制剂 Download PDF

Info

Publication number
CN109195989A
CN109195989A CN201780032522.1A CN201780032522A CN109195989A CN 109195989 A CN109195989 A CN 109195989A CN 201780032522 A CN201780032522 A CN 201780032522A CN 109195989 A CN109195989 A CN 109195989A
Authority
CN
China
Prior art keywords
antibody
cancer
inhibitor
ser
hnscc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780032522.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·纳伊特恩
A·莫罗佐夫
A·伍尔夫松
A·塔尔
K·钦
S·布拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Pfizer Inc
Original Assignee
Merck Patent GmbH
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Pfizer Inc filed Critical Merck Patent GmbH
Publication of CN109195989A publication Critical patent/CN109195989A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN201780032522.1A 2016-05-26 2017-05-22 用于癌症治疗的pd-1/pd-l1抑制剂 Pending CN109195989A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662341921P 2016-05-26 2016-05-26
US62/341,921 2016-05-26
US201662423358P 2016-11-17 2016-11-17
US62/423,358 2016-11-17
US201762471459P 2017-03-15 2017-03-15
US62/471,459 2017-03-15
PCT/EP2017/062213 WO2017202744A1 (en) 2016-05-26 2017-05-22 Pd-1 / pd-l1 inhibitors for cancer treatment

Publications (1)

Publication Number Publication Date
CN109195989A true CN109195989A (zh) 2019-01-11

Family

ID=58745241

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780032522.1A Pending CN109195989A (zh) 2016-05-26 2017-05-22 用于癌症治疗的pd-1/pd-l1抑制剂

Country Status (14)

Country Link
US (1) US20190144545A1 (https=)
EP (1) EP3464356A1 (https=)
JP (1) JP2019516748A (https=)
KR (1) KR20190012201A (https=)
CN (1) CN109195989A (https=)
AU (1) AU2017269675A1 (https=)
BR (1) BR112018073920A2 (https=)
CA (1) CA3025391A1 (https=)
IL (1) IL263178A (https=)
MX (1) MX2018014435A (https=)
RU (1) RU2018145184A (https=)
SG (1) SG11201810423XA (https=)
TW (1) TW201800108A (https=)
WO (1) WO2017202744A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018429A (zh) * 2019-12-24 2021-06-25 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
CN113164599A (zh) * 2018-12-24 2021-07-23 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
NZ733854A (en) 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
KR20190062515A (ko) * 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
MX2021005236A (es) * 2018-11-05 2021-06-18 Merck Sharp & Dohme Llc Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
EP3876940A1 (en) * 2018-11-05 2021-09-15 Pfizer Inc. Combinations for treating cancer
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
BR112022001045A2 (pt) * 2019-07-22 2022-07-19 Seagen Inc Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
US11718637B2 (en) 2020-03-20 2023-08-08 Gilead Sciences, Inc. Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
BR112022022335A2 (pt) 2020-05-05 2023-01-10 Teon Therapeutics Inc Moduladores de receptor canabinoide tipo 2 (cb2) e usos dos mesmos
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
KR20230128690A (ko) * 2022-02-28 2023-09-05 주식회사 시선테라퓨틱스 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물
EP4554943A1 (en) 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
NZ718821A (en) * 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
SG11201700074YA (en) * 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
NZ733854A (en) * 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
PH12017501857B1 (en) * 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMD SERONO: "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", 《CLINICALTRIALS.GOV.》 *
PFZER: "Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkins Lymphoma (JAVELIN HODGKINS)", 《CLINICALTRIALS.GOV》 *
SUMANTA K. PAL, MD，ET AL.: "Programmed Death-1 Inhibition in Renal Cell Carcinoma: Clinical Insights and Future Directions", 《CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164599A (zh) * 2018-12-24 2021-07-23 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CN113018429A (zh) * 2019-12-24 2021-06-25 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合

Also Published As

Publication number Publication date
WO2017202744A1 (en) 2017-11-30
BR112018073920A2 (pt) 2019-02-26
RU2018145184A (ru) 2020-06-26
IL263178A (en) 2018-12-31
KR20190012201A (ko) 2019-02-08
MX2018014435A (es) 2019-04-15
CA3025391A1 (en) 2017-11-30
SG11201810423XA (en) 2018-12-28
EP3464356A1 (en) 2019-04-10
TW201800108A (zh) 2018-01-01
AU2017269675A1 (en) 2019-01-17
JP2019516748A (ja) 2019-06-20
US20190144545A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
CN109195989A (zh) 用于癌症治疗的pd-1/pd-l1抑制剂
JP2021178822A (ja) がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤
JP2021506781A (ja) Ｉａｐアンタゴニスト及び抗ｐｄ−１分子による併用抗癌療法
CN109195990A (zh) 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
TW200831538A (en) VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
CN119789868A (zh) 用于癌的治疗和/或预防的药品
CN109908341A (zh) Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
CN109562163A (zh) Egfl6特异性单克隆抗体及其使用方法
US20190216923A1 (en) Methods and combination therapy to treat cancer
US20200368205A1 (en) Methods and combination therapy to treat cancer
RU2742312C1 (ru) Ингибиторы pd-1 / pd-l1 для лечения рака
HK40040793A (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
HK40001950A (en) Pd-1 / pd-l1 inhibitors for cancer treatment
HK1242210A1 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001950

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190111

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40001950

Country of ref document: HK